
Overview
Integer fiscal Q2 sales rise 11% to $476 mln, beating analyst expectations
Adjusted EPS for fiscal Q2 meets analyst estimates, per LSEG data
Company raises 2025 adjusted operating income and EPS outlook at the midpoint
Outlook
Integer sees 2025 adjusted EPS of $6.25 to $6.51, a growth of 18%-23%
Company expects 2025 adjusted operating income growth of 12%-16%
Integer projects 2025 sales between $1.85 bln and $1.88 bln
Company anticipates 2025 cash flow from operations of $235 mln to $255 mln
Result Drivers
CARDIO & VASCULAR - Sales rose 24% driven by new product ramps and acquisitions
NEUROMODULATION - Growth supported by emerging customers with PMA (pre-market approval) products
PORTABLE MEDICAL EXIT - Sales in Other Markets fell 38% due to planned exit
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $476 mln | $464.40 mln (9 Analysts) |
Q2 Adjusted EPS | Meet | $1.55 | $1.55 (8 Analysts) |
Q2 Adjusted Net Income | Miss | $55 mln | $55.10 mln (7 Analysts) |
Press Release: ID:nGNX79x8RR